Origin Agritech (SEED) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
2 Feb, 2026Executive summary
Fiscal year 2025 marked a transformative period with a full recovery in team, research, production, and sales infrastructure.
A three-stage strategic plan was launched: recovery (2025–2026), stand up (2027–2029), and return to industry leadership (2030–2032).
Senior leadership team fully in place; headcount increased from 68 to 97 professionals.
Formed a three-way R&D partnership with top agricultural institutions to drive corn variety innovation.
Launched four new corn varieties, with several receiving regulatory approvals in key provinces.
Financial highlights
Total revenues for fiscal year 2025 were CNY 91.3 million (US$12.9 million), a 90% decrease from the previous year.
Net loss attributable to the company was CNY 53.3 million (US$7.5 million), compared to net income of CNY 20.7 million (US$3.0 million) in FY2024.
Cash and cash equivalents increased by 89% to CNY 15.9 million (US$2.2 million) as of September 30, 2025.
Operating expenses increased to CNY 64.2 million (US$9.0 million) from CNY 52.7 million (US$7.5 million) year-over-year.
Revenue decline attributed to equipment upgrades and reduced external seed production services.
Outlook and guidance
Strategic investments in technology, infrastructure, and people are expected to drive sustainable long-term growth.
The company is confident that recent decisions will deliver significant value to shareholders and farmers.
Strategic plan targets recovery in 2025–2026, growth from 2027–2029, and industry leadership by 2030–2032.
Commercialization of GMOs and gene editing accelerated through alliances and facility upgrades.
Latest events from Origin Agritech
- Biotech seed firm with VIE structure plans $30M shelf offering amid regulatory and financial risks.SEED
Registration Filing2 Feb 2026 - Biotech seed firm targets $30M raise amid regulatory shifts and ongoing financial volatility.SEED
Registration Filing2 Feb 2026 - Biotech seed firm targets $30M raise amid regulatory, VIE, and financial risks in China.SEED
Registration Filing2 Feb 2026